FDA accepts Cingulate's drug application for ADHD treatment CTx-1301 Oct 14, 2025 08:04AM
Cingulate secures exclusive US manufacturing deal for ADHD treatment Sep 17, 2025 08:45AM
Cingulate places CEO on administrative leave, names interim leadership Aug 15, 2025 09:02AM
Cingulate submits FDA application for ADHD drug CTx-1301 Aug 6, 2025 08:45AM
Cingulate receives $4.3 million FDA fee waiver for ADHD drug application Jul 29, 2025 08:01AM


Jul 9, 2025 08:03AM Cingulate names Nilay Patel as chief legal officer ahead of FDA filing
May 20, 2025 08:03AM Cingulate Inc (CING): Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
May 14, 2025 08:04AM Cingulate Inc (CING): FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
Apr 9, 2025 08:00AM Cingulate Inc (CING) Receives $3M Grant from Private Foundation
Apr 3, 2025 08:06AM Cingulate Inc (CING) Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
Mar 4, 2025 09:02AM Cingulate Inc (CING) Reports Safety Results from Final Phase 3 Trials for CTx-1301
Aug 15, 2024 07:45AM Cingulate Inc (CING) Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
Jun 28, 2024 09:16AM Cingulate Inc (CING) Receives $1.86M from Warrant Exercise
Jun 25, 2024 09:20AM Cingulate (CING) Achieves Key Manufacturing Milestone in the Development of CTx-1301